Details for New Drug Application (NDA): 216435
✉ Email this page to a colleague
NDA 216435 describes EDETATE CALCIUM DISODIUM, which is a drug marketed by Casper Pharma Llc and is included in one NDA. It is available from one supplier. Additional details are available on the EDETATE CALCIUM DISODIUM profile page.
The generic ingredient in EDETATE CALCIUM DISODIUM is edetate calcium disodium. There are two drug master file entries for this compound. One supplier is listed for this compound. Additional details are available on the edetate calcium disodium profile page.
The generic ingredient in EDETATE CALCIUM DISODIUM is edetate calcium disodium. There are two drug master file entries for this compound. One supplier is listed for this compound. Additional details are available on the edetate calcium disodium profile page.
Summary for 216435
| Tradename: | EDETATE CALCIUM DISODIUM |
| Applicant: | Casper Pharma Llc |
| Ingredient: | edetate calcium disodium |
| Patents: | 0 |
Pharmacology for NDA: 216435
| Mechanism of Action | Calcium Chelating Activity Lead Chelating Activity |
| Physiological Effect | Decreased Coagulation Factor Activity |
Suppliers and Packaging for NDA: 216435
| Tradename | Generic Name | Dosage | NDA | Application Type | Supplier | National Drug Code | Package Code | Package |
|---|---|---|---|---|---|---|---|---|
| EDETATE CALCIUM DISODIUM | edetate calcium disodium | INJECTABLE;INJECTION | 216435 | ANDA | Rising Pharma Holdings, Inc. | 64980-588 | 64980-588-51 | 5 VIAL in 1 CARTON (64980-588-51) / 5 mL in 1 VIAL (64980-588-05) |
Profile for product number 001
| Active Rx/OTC/Discontinued: | RX | Dosage: | INJECTABLE;INJECTION | Strength | 200MG/ML | ||||
| Approval Date: | May 3, 2023 | TE: | RLD: | No | |||||
Complete Access Available with Subscription
